InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Bunk post# 224147

Wednesday, 09/07/2016 5:00:32 AM

Wednesday, September 07, 2016 5:00:32 AM

Post# of 346721
We know now that this was likely Blackrock selling back those shares and Peregrine BOD rec'd cheap options in 2015 because of the way the BlackRock financing was set up and if all is true ....where BlackRock is at the end of selling their pile of shares then we should see a major correction to the upside. Do we like the way this game is playing out? Well....we have not seen the final puzzle pieces yet and hopefully, with these last couple years it has given some like AstraZeneca a chance to see the big future with PS Targeting.

Now do we get to see the terms of the BlackRock deal? Is this BlackRock doing as what was promised? I am sure BlackRock likes selling back the shares that were shorted at the price difference from $1.08 down to this .3x range and if they have come to understand how valuable PS Targeting will become....

Will BlackRock make an even bigger deal on the longterm hold side ...of Peregrine?

The due diligence has already been completed and now with trials such as with NCCN begin to surface some big buys with BlackRock or AstraZeneca or State Street or Kennedy Capital Management or a Koch full of others just may help all forget about any RS talk.


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News